Suchergebnisse - "Salpini, Romina"

PubPharm (12)

1

Targeting SARS-CoV-2 Main Protease : A Successful Story Guided by an In Silico Drug Repurposing Approach

enthalten in: Journal of chemical information and modeling | 2023

von Ambrosio, F. | Costa, G. | Romeo, I. | +10

2

Targeting SARS-CoV-2 nsp13 Helicase and Assessment of Druggability Pockets : Identification of Two Potent Inhibitors by a Multi-Site In Silico Drug Repurposing Approach

enthalten in: Molecules (Basel, Switzerland) | 2022

von Romeo, I. | Ambrosio, F. | Costa, G. | +11

3

Key genetic elements, single and in clusters, underlying geographically dependent SARS-CoV-2 genetic adaptation and their impact on binding affinity for drugs and immune control

enthalten in: The Journal of antimicrobial chemotherapy | 2021

von Salpini, R. | Alkhatib, M. | Costa, G. | +11

4

Current status of antivirals and druggable targets of SARS CoV-2 and other human pathogenic coronaviruses

enthalten in: Drug resistance updates : reviews and commentaries in antimicrobial and anticancer chemotherapy | 2020

von Artese, A. | Svicher, V. | Costa, G. | +8

5

Hepatitis B virus reactivation sustained by a hepatitis B virus surface antigen immune-escape mutant isolate in a patient who was hepatitis B core antibody positive during treatment with sofosbuvir and velpatasvir for hepatitis C virus infection : a case report

enthalten in: Journal of medical case reports | 2019

von Foroghi Biland, L. | Ferrari, L. | Malagnino, V. | +8

6

HDV Can Constrain HBV Genetic Evolution in HBsAg : Implications for the Identification of Innovative Pharmacological Targets

enthalten in: Viruses | 2018

von Colagrossi, L. | Salpini, R. | Scutari, R. | +32

7

Immune-escape mutations and stop-codons in HBsAg develop in a large proportion of patients with chronic HBV infection exposed to anti-HBV drugs in Europe

enthalten in: BMC infectious diseases | 2018

von Colagrossi, L. | Hermans, L. | Salpini, R. | +37

8

Combined Analysis of the Prevalence of Drug-Resistant Hepatitis B Virus in Antiviral Therapy-Experienced Patients in Europe (CAPRE)

enthalten in: The Journal of infectious diseases | 2016

von Hermans, L. | Svicher, V. | Pas, S. | +35

9

Late hepatitis B virus reactivation after lamivudine prophylaxis interruption in an anti-HBs-positive and anti-HBc-negative patient treated with rituximab-containing therapy

enthalten in: The Journal of infection | 2012

von Ceccarelli, L. | Salpini, R. | Sarmati, L. | +7

10

HCV genotypes are differently prone to the development of resistance to linear and macrocyclic protease inhibitors

enthalten in: PloS one | 2012

von Cento, V. | Mirabelli, C. | Salpini, R. | +15